What Is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone released by the intestines when we have a meal. Semaglutide was developed by Novo Nordisk and was first approved by the FDA in 2017 under the brand name Ozempic for the treatment of type 2 diabetes. Weight loss was one of the major beneficial effects for people with diabetes. In 2021, Novo Nordisk sought approval specifically for chronic weight management under the brand name Wegovy.
Semaglutide has a long half-life of seven days, achieved through structural modifications, including an amino acid substitution and the addition of a fatty acid chain that promotes albumin binding. The pharmacological profile means that the drug is dosed once weekly, rather than once daily as required by older analogs like liraglutide. See our liraglutide vs semaglutide comparison for a full breakdown of the differences.
The primary human benefits of semaglutide include:
- Significant and sustained weight loss (average 13 to 20% of body weight in clinical trials)
- Improved glycemic control and HbA1c reduction
- Cardiovascular risk reduction in diabetic populations taking injectable formulations
- Decreased appetite and food cravings
- Potential neuroprotective effects that are currently under investigation
How It Works
GLP-1 Receptor Activation
Semaglutide functions as a potent agonist at GLP-1 receptors distributed throughout the body, including the pancreas, brain, heart, and gastrointestinal tract. Upon binding to pancreatic beta-cell receptors, it stimulates glucose-dependent insulin secretion while simultaneously suppressing glucagon release from alpha cells. This dual action improves postprandial glucose control without the risk of hypoglycemia associated with some other types of diabetes medications.
Appetite Suppression and Satiety Enhancement
The weight-loss effects of semaglutide are primarily mediated by central nervous system mechanisms. GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety signals. Semaglutide does not cross the blood-brain barrier; however, it modulates appetite by sending signals to the brain that reduce appetite, increase feelings of fullness after smaller meals, and diminish food-reward pathways that drive hedonic eating behaviors.
Gastric Emptying Delay
Semaglutide significantly slows the rate at which food leaves the stomach, contributing to prolonged feelings of fullness and reduced caloric intake. Delayed gastric emptying also blunts post-meal glucose spikes by slowing carbohydrate absorption. These effects are beneficial for weight management, but this mechanism also underlies some gastrointestinal side effects experienced during treatment initiation.
Cardiovascular and Metabolic Effects
Beyond glucose and weight management, semaglutide demonstrates direct cardiovascular benefits. The SUSTAIN-6 and SELECT trials demonstrated reduced rates of major adverse cardiovascular events, including myocardial infarction and stroke, in treated populations. Additional metabolic improvements include reductions in systolic blood pressure, triglycerides, and inflammatory markers.
“Semaglutide's multi-system mechanism of action is what sets it apart from earlier weight loss drugs. The combination of central appetite suppression via hypothalamic GLP-1 receptors, peripheral glucose-dependent insulin secretion, and delayed gastric motility produces durable weight reduction without the cardiovascular risks that plagued older agents like sibutramine.”
